ClinicalTrials.gov record
Active, not recruiting Phase 1 Interventional

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

ClinicalTrials.gov ID: NCT03531736

Public ClinicalTrials.gov record NCT03531736. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 6:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Allogeneic Hematopoietic Stem Cell Transplantation of α/β T-Lymphocyte Depleted Graft Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

Study identification

NCT ID
NCT03531736
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Enrollment
17 participants

Conditions and interventions

Interventions

  • Allogeneic Hematopoietic Stem Cell Transplantation Procedure
  • Antithymocyte globulin (Rabbit) Drug
  • Rituxan Drug
  • cyclophosphamide Drug
  • fludarabine Drug
  • total body irradiation Radiation

Procedure · Drug · Radiation

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 8, 2018
Primary completion
Apr 30, 2026
Completion
Apr 30, 2026
Last update posted
Aug 18, 2025

2018 – 2026

United States locations

U.S. sites
2
U.S. states
2
U.S. cities
2
Facility City State ZIP Site status
Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown New Jersey 07748
Memorial Sloan Kettering Cancer Center New York New York 10065

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03531736, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 18, 2025 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03531736 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →